204 related articles for article (PubMed ID: 27588129)
21. The Hippo Signaling Pathway in Pancreatic Cancer.
Ansari D; Ohlsson H; Althini C; Bauden M; Zhou Q; Hu D; Andersson R
Anticancer Res; 2019 Jul; 39(7):3317-3321. PubMed ID: 31262852
[TBL] [Abstract][Full Text] [Related]
22. Yes-associated protein 1 is required for proliferation and function of bovine granulosa cells in vitro†.
Plewes MR; Hou X; Zhang P; Liang A; Hua G; Wood JR; Cupp AS; Lv X; Wang C; Davis JS
Biol Reprod; 2019 Nov; 101(5):1001-1017. PubMed ID: 31350850
[TBL] [Abstract][Full Text] [Related]
23. The Hippo-YAP/TAZ Signaling Pathway in Intestinal Self-Renewal and Regeneration After Injury.
Deng F; Wu Z; Zou F; Wang S; Wang X
Front Cell Dev Biol; 2022; 10():894737. PubMed ID: 35927987
[TBL] [Abstract][Full Text] [Related]
24. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
25. Physiological and pathological roles of the Hippo-YAP/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis.
Nishina H
Cancer Sci; 2022 Jun; 113(6):1900-1908. PubMed ID: 35349740
[TBL] [Abstract][Full Text] [Related]
26. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
[TBL] [Abstract][Full Text] [Related]
27. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis.
Moroishi T; Park HW; Qin B; Chen Q; Meng Z; Plouffe SW; Taniguchi K; Yu FX; Karin M; Pan D; Guan KL
Genes Dev; 2015 Jun; 29(12):1271-84. PubMed ID: 26109050
[TBL] [Abstract][Full Text] [Related]
28. Thromboxane A2 Activates YAP/TAZ Protein to Induce Vascular Smooth Muscle Cell Proliferation and Migration.
Feng X; Liu P; Zhou X; Li MT; Li FL; Wang Z; Meng Z; Sun YP; Yu Y; Xiong Y; Yuan HX; Guan KL
J Biol Chem; 2016 Sep; 291(36):18947-58. PubMed ID: 27382053
[TBL] [Abstract][Full Text] [Related]
29. Proliferation of hepatic stellate cells, mediated by YAP and TAZ, contributes to liver repair and regeneration after liver ischemia-reperfusion injury.
Konishi T; Schuster RM; Lentsch AB
Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G471-G482. PubMed ID: 29351389
[TBL] [Abstract][Full Text] [Related]
30. Hippo pathway effectors YAP/TAZ as novel determinants of ferroptosis.
Yang WH; Chi JT
Mol Cell Oncol; 2020; 7(1):1699375. PubMed ID: 31993503
[TBL] [Abstract][Full Text] [Related]
31. YAP/TAZ: a promising target for squamous cell carcinoma treatment.
Dong X; Meng L; Liu P; Ji R; Su X; Xin Y; Jiang X
Cancer Manag Res; 2019; 11():6245-6252. PubMed ID: 31360073
[TBL] [Abstract][Full Text] [Related]
32. miR-582-5p Is a Tumor Suppressor microRNA Targeting the Hippo-YAP/TAZ Signaling Pathway in Non-Small Cell Lung Cancer.
Zhu B; V M; Finch-Edmondson M; Lee Y; Wan Y; Sudol M; DasGupta R
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670427
[TBL] [Abstract][Full Text] [Related]
33. Targeted inhibition of YAP/TAZ alters the biological behaviours of keloid fibroblasts.
Gao N; Lu L; Ma X; Liu Z; Yang S; Han G
Exp Dermatol; 2022 Mar; 31(3):320-329. PubMed ID: 34623712
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of TAZ and YAP crosstalk with TGFβ signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression.
Luu AK; Schott CR; Jones R; Poon AC; Golding B; Hamed R; Deheshi B; Mutsaers A; Wood GA; Viloria-Petit AM
BMC Vet Res; 2018 Nov; 14(1):365. PubMed ID: 30477496
[TBL] [Abstract][Full Text] [Related]
35. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
36. TAZ promotes cell growth and inhibits Celastrol-induced cell apoptosis.
Wang S; Ma K; Chen L; Zhu H; Liang S; Liu M; Xu N
Biosci Rep; 2016 Oct; 36(5):. PubMed ID: 27515420
[TBL] [Abstract][Full Text] [Related]
37. Hippo-YAP1 Is a Prognosis Marker and Potentially Targetable Pathway in Advanced Gallbladder Cancer.
García P; Rosa L; Vargas S; Weber H; Espinoza JA; Suárez F; Romero-Calvo I; Elgueta N; Rivera V; Nervi B; Obreque J; Leal P; Viñuela E; Aguayo G; Muñiz S; Sagredo A; Roa JC; Bizama C
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218280
[TBL] [Abstract][Full Text] [Related]
38. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
39. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
40. New insights into the ambivalent role of YAP/TAZ in human cancers.
Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]